Press release - 18/09/2009 How HIV disables immune cells In order to be able to ward off disease pathogens, immune cells must be mobile and able to establish contact with each other. Professor Dr. Oliver Fackler’s group of researchers in the Department of Virology of the Institute of Hygiene at the University of Heidelberg has discovered a mechanism in an animal model revealing how HI viruses cripple immune cells: The mobility of cells is inhibited by the protein Nef. The study, which was published in…https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-hiv-disables-immune-cells
Dossier - 30/07/2009 Downstream processing: bottleneck purification process The fermentation processes that are used by biopharmaceutical manufacturers have shown to lead to increasing quantities of therapeutic proteins. However this increase in turn leads to capacity bottlenecks in the subsequent purification process known as downstream processing and is associated with high costs. Downstream processing comprises up to 80 per cent of the entire production costs. Producers are increasingly recognising the present need…https://www.gesundheitsindustrie-bw.de/en/article/dossier/downstream-processing-bottleneck-purification-process
Dossier - 29/11/2010 Drug safety and the difficulty of making ends meet Everybody wants safe drugs – manufacturers, doctors and patients. However, many dangers, both avoidable and unavoidable, make medicinal treatment a high-risk process, despite all best efforts and assertions. Not enough information on drug-related risks is available, and the estimated number of adverse drug reactions that go unreported is quite high.https://www.gesundheitsindustrie-bw.de/en/article/dossier/drug-safety-and-the-difficulty-of-making-ends-meet
Article - 18/12/2012 Gene therapy medicinal products: the first gene therapy product has been approved – where does the future lie? Is gene therapy close to broad clinical application? Following negative headlines at the end of the 1990s gene therapy had almost disappeared from the public radar to become an issue almost exclusively dealt with by research laboratories. Gene therapy has now reappeared in the public domain since the European Medicines Agency EMA gave the Dutch biotech company uniQure the go-ahead for the application of somatic gene therapy for the treatment of a…https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapy-medicinal-products-the-first-gene-therapy-product-has-been-approved-where-does-the-futu